

## ASX ANNOUNCEMENT

### Benitec Biopharma to present at two US-based investor conferences

#### Key Points:

- Benitec's CEO to present at Cowen's Investor Showcase in San Francisco
- Benitec's CBO to present at Cappello's Investment Conference in Los Angeles
- Opportunity to inform US institutional investors of Benitec's progress and recent near-clinical program acquisition in HCV.

**Sydney, Australia January 8, 2013:** Benitec Biopharma Ltd (ASX: BLT) today announced that the company would present scientific and commercial updates at two investor conferences in California this week.

Benitec's Chief Executive Officer, Dr Peter French, will address US-based investment bank Cowen and Company's Asia Pacific Life Science Showcase in San Francisco on Monday local time. The Showcase is annexed to the JP Morgan Healthcare Conference. Dr French will provide an update on Benitec's programs, in particular its newly-acquired Hepatitis C program.

On Friday Benitec's Chief Business Officer, Mr Carl Stubbings, will be presenting at Cappello Capital's, Australia-US Investment Conference, which is to be held in conjunction with the "G'DAY USA" program in Los Angeles. The audience will be mostly comprised of institutional investors.

A copy of both presentations is available on Benitec's website

#### For more information please contact:

Carl Stubbings | Benitec Chief Business Officer  
Phone: +61 (02) 9555 6986 | [cstubbings@benitec.com](mailto:cstubbings@benitec.com) | [www.benitec.com](http://www.benitec.com)

#### About Benitec Biopharma

Benitec Biopharma Ltd is developing novel treatments for chronic and life-threatening conditions based on gene-silencing technology which is targeted and transformational, called DNA-directed RNA interference (ddRNAi) or expressed RNAi. The technology's potential results from its demonstrated ability to permanently silence genes that cause the conditions. Importantly, the genes and gene pathways being targeted by ddRNAi have rarely been the subject of therapeutic research using small molecule agents, on which most of today's pharmaceutical products are based.

Benitec Biopharma trades on the Australian Securities Exchange (ASX) under the symbol "BLT". The company aims to deliver a range of novel ddRNAi-based therapeutics to the clinic in partnership with the pharmaceutical industry. In addition to a focused R&D strategy in infectious diseases, cancer and chronic cancer-associated pain, Benitec Biopharma has licensed its ddRNAi-based gene silencing technology to a number of licensees who are progressing their programs towards the clinic.